treating homologous recombination proficient ovarian cancer
Published 3 years ago • 111 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
1:25
dr. borst on homologous recombination deficiency in patients with ovarian cancer
-
8:41
impact of hrd status on frontline treatment of ovarian cancer
-
6:08
treating ovarian cancer based on hrd status
-
6:28
ovarian cancer: what is the role of hrd testing?
-
4:42
treatment of hrd-negative ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
1:13:10
the state of ovarian cancer: exploring the landscape of systemic therapy
-
7:34
parp inhibition’s role in recurrent ovarian cancer
-
2:32
dr. moore on research evaluating repeat exposure to parp inhibition in ovarian cancer
-
45:27
what is hrd (homologous recombination deficiency) and how does it impact ovarian cancer?
-
7:30
somatic mutation testing for ovarian cancer
-
1:36
jerry lanchbury, phd, describes myriad's hrd test
-
1:11
dr. rana on genetic testing guidelines for patients with ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
9:08
factors in choice of treatment for recurrent ovarian cancer
-
7:15
systemic management of ovarian cancer: closing thoughts
-
3:09
patient preference for treatment in ovarian cancer
-
6:43
sequencing parp inhibitors in advanced ovarian cancer
-
0:54
dr. salani on the progression of upfront ovarian cancer treatment